The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer
Authors' conclusion
Assessment of TLA from 68Ga-DOTATATE PET/CT may predict survival. SST2 IHC was not correlated with 68Ga-DOTATATE avidity. Metastatic disease may be optimally assessed by concurrent 18F-FDG and 68Ga-DOTATATE imaging.
Study context
- Population
- Patients with medullary thyroid cancer (MTC); subgroup of 37 with 68Ga-DOTATATE positron emission tomography (PET)/computed tomography (CT), 13 with contemporaneous 18F-FDG-PET/CT
- Participants
- 103 patients
- Outcome
- SST2 and SST5 IHC expression
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
- Positive SST2 expression
- 42 (41%)
- Positive SST5 immunohistochemistry (IHC)
- 45 (44%)
- Both SST2 and SST5 expressed
- 17 (17%)
- Shorter survival associated with total lesion activity (TLA) >20
- P = .04
Observational data: associations, not effects.
Further findings
- RET-negative status appeared to have shorter survival (not significant)
- P = 0.12
Original publication
The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer. Endocr Pract. Published 14 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →